Inhibition of pancreatic lipase by berberine and dihydroberberine: An investigation by docking simulation and experimental validation

Medicinal Chemistry Research

Volumn 22, Issue 5, 2013, Pages 2273-2278

  Mohammad, Mohammad ^a   Al Masri, Ihab M ^b   Issa, Ala ^a   Khdair, Ayman ^c   Bustanji, Yasser ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

^b AL AZHAR UNIVERSITY   (Palestine)

^c APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

Author keywords

Berberine; Dihydroberberine; Docking simulations; Enzyme inhibition; Obesity; Pancreatic lipase

Indexed keywords

BERBERINE; BERBERINE DERIVATIVE; CATION; DIHYDROBERBERINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; ENZYME BINDING; ENZYME INHIBITION; HYDRATION; IC 50; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; VALIDATION PROCESS;

EID: 84879692382     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0221-9     Document Type: Article

References (31)

1. Arbeeny CM (2004) Addressing the unmet medical need for safe and effective weight loss therapies. Obes Res 12:1191-1196
2. Ballinger A, Peikin SR (2002) Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 440:109-117
3. Birari RB, Bhutani KK (2007) Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today 12:879-889
4. Bray GA, Tartaglia LA (2000) Medicinal strategies in the treatment of obesity. Nature 404:672-677
5. Bustanji Y, Taha MO, Yousef AM, Al-Bakri AG (2006) Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation. J Enzym Inhib Med Chem 21:163-171
6. Bustanji Y, Issa A, Mohammad M, Hudaib M, Tawah K, Alkhatib H, Almasri I, Al-Khalidi B (2010) Inhibition of hormone sensitive lipase and pancreatic lipase by Rosmarinus officinalis extract and selected phenolic constituents. J Med Plants Res 4:2235-2242
7. Bustanji Y, Al-Masri IM, Mohammad M, Hudaib M, Tawaha K, Tarazi H, AlKhatib HS (2011a) Pancreatic lipase inhibition activity of trilactone terpenes of Ginkgo biloba. J Enzym Inhib Med Chem 26:453-459
8. Bustanji Y, Mohammad M, Hudaib M, Tawaha K, Al-Masri IM, AlKhatib HS, Issa A, Alali F (2011b) Screening of some medicinal plants for their pancreatic lipase inhibitory potential Jordan. J Pharm Sci 4:81-88
9. Cairns E (2005) Obesity: the fat lady sings? Drug Discov Today 10:305-307
10. Cooke D, Bloom S (2006) The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 5:919-931
11. Drent ML, Larsson I, Williamolsson T, Quaade F, Czubayko F, Vonbergmann K, Strobel W, Sjostrom L, Vanderveen EA (1995) Orlistat (Ro-18-0647), a lipase inhibitor, in the treatment of human obesity - a multiple-dose Study. Int J Obes 19:221-226
12. Egloff MP, Marguet F, Buono G, Verger R, Cambillau C, Vantilbeurgh H (1995) The 2.46-Angstrom resolution structure of the pancreatic lipase-colipase complex inhibited by a C-11 alkyl phosphonate. Biochemistry 34:2751-2762
13. Foster-Schubert KE, Cummings DE (2006) Emerging therapeutic strategies for obesity. Endocr Rev 27:779-793
14. FRED VUM (2006) OpenEye Scientific Software (www.eyesopen.com), Boston
15. Gurevich-Panigrahi T, Panigrahi S, Wiechec E, Los M (2009) Obesity: pathophysiology and clinical management. Curr Med Chem 16:506-521
16. Halford JCG (2006a) Obesity drugs in clinical development. Curr Opin Investig D 7:312-318
17. Halford JCG (2006b) Pharmacotherapy for obesity. Appetite 46:6-10
18. Hofbauer K (2002) Molecular pathways to obesity. Int J Obes 26:S18-S27
19. Hu YS, Davies GE (2010) Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia 81:358-366
20. Issa A, Mohammad M, Hudaib M, Tawah K, Abu Rjai T, Oran S, Bustanji Y (2011) A potential role of Lavandula angustifolia in the management of diabetic dyslipidemia. J Med Plants Res 5:3876-3882
21. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB (2009) Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol-Endocrinol Metab 296:E812-E819
22. Kong WJ, Wei J, Abidi P, Lin MH, Inaba S, Li C, Wang YL, Wang ZZ, Si SY, Pan HN, Wang SK, Wu JD, Wang Y, Li ZR, Liu JW, Jiang JD (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10:1344-1351
23. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55:2256-2264
24. Manly CJ, Chandrasekhar J, Ochterski JW, Hammer JD, Warfield BB (2008) Strategies and tactics for optimizing the Hit-to-Lead process and beyond - a computational chemistry perspective. Drug Discov Today 13:99-109
25. Mukherjee M (2003) Human digestive and metabolic lipases - a brief review. J Mol Catal B Enzym 22:369-376
26. OMEGA VUM (2006) OpenEye Scientific Software Inc., Santa Fe, July, 2006
27. Shi YG, Burn P (2004) Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 3:695-710
28. Vantilbeurgh H, Sarda L, Verger R, Cambillau C (1992) Structure of the pancreatic lipase procolipase complex. Nature 359:159-162
29. Vega GL (2001) Obesity, the metabolic syndrome, and cardiovascular disease. Am Heart J 142:1108-1116
30. Vuddanda PR, Chakraborty S, Singh S (2010) Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Inv Drug 19:1297-1307
31. Winkler FK, Darcy A, Hunziker W (1990) Structure of human pancreatic lipase. Nature 343:771-774